PHP
TGTX icon

Parkman Healthcare Partners’s TG Therapeutics TGTX Stock Holding History

Parkman Healthcare Partners’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-126,471
Closed -$2.96M – 99
2024
Q3 		$2.96M Sell
126,471
-53,849
-30% -$1.18M 0.38% 66
2024
Q2 		$3.21M Buy
180,320
+25,281
+16% +$403K 0.43% 65
2024
Q1 		$2.36M Sell
155,039
-50,278
-24% -$801K 0.29% 81
2023
Q4 		$3.51M Sell
205,317
-4,002
-2% -$46.5K 0.49% 61
2023
Q3 		$1.75M Sell
209,319
-11,315
-5% -$158K 0.32% 81
2023
Q2 		$5.48M Sell
220,634
-55,007
-20% -$1.42M 0.95% 32
2023
Q1 		$4.15M Buy
+275,641
New +$4.19M 0.9% 40

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Parkman Healthcare Partners's TGTX Position: Q4 2024 in Review

Parkman Healthcare Partners sold out of TG Therapeutics (TGTX) in Q4 2024, closing a stake of 126,471 shares — an estimated $2.96M sold.

Parkman Healthcare Partners first reported a position in TGTX in Q1 2023 and held it in 7 quarters. The position peaked at $5.48M in Q2 2023. 331 funds tracked by Wall St. Rank hold TGTX as of Q4 2024.

  • Parkman Healthcare Partners reported no remaining TG Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Parkman Healthcare Partners sold 126,471 TG Therapeutics shares in Q4 2024, an estimated $2.96M.
  • Parkman Healthcare Partners first reported a position in TG Therapeutics in Q1 2023 and held it in 7 quarters.
  • Parkman Healthcare Partners's TG Therapeutics position peaked at $5.48M in Q2 2023.
  • 331 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2024.

Based on Parkman Healthcare Partners's 13F filing for Q4 2024, filed 14 Feb 2025.